| Literature DB >> 23717271 |
Alice B Loughridge1, Benjamin N Greenwood, Heidi E W Day, Matthew B McQueen, Monika Fleshner.
Abstract
Serotonin (5-HT) is implicated in the development of stress-related mood disorders in humans. Physical activity reduces the risk of developing stress-related mood disorders, such as depression and anxiety. In rats, 6 weeks of wheel running protects against stress-induced behaviors thought to resemble symptoms of human anxiety and depression. The mechanisms by which exercise confers protection against stress-induced behaviors, however, remain unknown. One way by which exercise could generate stress resistance is by producing plastic changes in gene expression in the dorsal raphe nucleus (DRN). The DRN has a high concentration of 5-HT neurons and is implicated in stress-related mood disorders. The goal of the current experiment was to identify changes in the expression of genes that could be novel targets of exercise-induced stress resistance in the DRN. Adult, male F344 rats were allowed voluntary access to running wheels for 6 weeks; exposed to inescapable stress or no stress; and sacrificed immediately and 2 h after stressor termination. Laser capture micro dissection selectively sampled the DRN. mRNA expression was measured using the whole genome Affymetrix microarray. Comprehensive data analyses of gene expression included differential gene expression, log fold change (LFC) contrast analyses with False Discovery Rate correction, KEGG and Wiki Web Gestalt pathway enrichment analyses, and Weighted Gene Correlational Network Analysis (WGCNA). Our results suggest that physically active rats exposed to stress modulate expression of twice the number of genes, and display a more rapid and strongly coordinated response, than sedentary rats. Bioinformatics analyses revealed several potential targets of stress resistance including genes that are related to immune processes, tryptophan metabolism, and circadian/diurnal rhythms.Entities:
Keywords: Affymetrix gene microarray; Weighted Gene Correlational Network Analysis; bioinformatics; dorsal raphe nucleus; laser capture microdissection; stress resistance
Year: 2013 PMID: 23717271 PMCID: PMC3650681 DOI: 10.3389/fnbeh.2013.00037
Source DB: PubMed Journal: Front Behav Neurosci ISSN: 1662-5153 Impact factor: 3.558
Figure 1Number of genes differentially expressed by a log fold change ≥ ± 1.1 in rats exposed to stress compared to home cage non-stressed controls. (A) Total number of genes differentially expressed and (B) Number of genes differentially upregulated or downregulated.
Figure 3Effect of physical activity status on stress-induced differential gene expression in the DRN by Number of genes differentially expressed immediately following (red) and 2 hours post (blue) stress, and genes differentially expressed at both time points (purple).
Functionally enriched KEGG and Wiki pathway categories related to genes differentially expressed in physically active and sedentary rats immediately following and 2 h post stress.
| Olfactory transduction:04740 | 19 | 2.80en–08 |
| Pathways in cancer:05200 | 8 | 0.0001 |
| Metabolic pathways:01100 | 15 | 0.0001 |
| Allograft rejection:05330 | 4 | 0.0001 |
| MAPK signaling pathway:04010 | 7 | 0.0002 |
| Autoimmune thyroid disease:05320 | 4 | 0.0003 |
| VEGF signaling pathway:04370 | 4 | 0.0004 |
| Intestinal immune network for IgA production:04672 | 3 | 0.0010 |
| C21-Steroid hormone metabolism:00140 | 2 | 0.0014 |
| Graft-vs. host disease:05332 | 3 | 0.0022 |
| Diurnally regulated genes with circadian orthologs:WP1306 | 3 | 0.0006 |
| B cell receptor signaling pathway:WP285 | 4 | 0.0040 |
| Cytokine and inflammatory response:WP271 | 2 | 0.0040 |
| Tryptophan metabolism:WP270 | 2 | 0.0128 |
| Regulation of actin cytoskeleton:WP351 | 3 | 0.0201 |
| TGF beta signaling pathway:WP505 | 2 | 0.0195 |
| MAPK signaling pathway:WP358 | 3 | 0.0238 |
| Kit receptor signaling pathway:WP147 | 2 | 0.0309 |
| IL-5 signaling pathway:WP44 | 2 | 0.0318 |
| GPCRs, class A rhodopsin-like:WP473 | 3 | 0.0564 |
Figure 2Number of genes differentially expressed by Total number of genes differentially expressed. (B) Number of genes differentially upregulated or downregulated.
KEGG functionally enriched pathway categories generated from genes significantly differentially expressed at .
| Olfactory transduction:04740 | 70 | 1.65e–13 |
| Ribosome:03010 | 18 | 9.81e–12 |
| Metabolic pathways:01100 | 69 | 1.48e–10 |
| MAPK signaling pathway:04010 | 23 | 6.84e–07 |
| Neuroactive ligand receptor interaction:04080 | 20 | 1.92e–05 |
| Pathways in cancer:05200 | 23 | 2.34e–05 |
| Endocytosis:04144 | 17 | 5.79e–05 |
| TGF beta signaling pathway:04350 | 10 | 6.16e–05 |
| ErbB signaling pathways:04012 | 10 | 0.0001 |
| Arachidonic acid metabolism:00590 | 9 | 0.0010 |
| Olfactory transduction:04740 | 66 | 1.78e–21 |
| Allograft rejection:05330 | 8 | 7.41e–06 |
| Pathways in cancer:05200 | 18 | 1.16e–05 |
| Autoimmune thyroid disease:05320 | 8 | 2.27e–05 |
| Graft-vs.-host disease:05332 | 7 | 5.39e–05 |
| C21-Steroid hormone metabolism:00140 | 4 | 4.44e–05 |
| Androgen and estrogen metabolism:00150 | 6 | 3.77e–05 |
| Type I diabetes mellitus:04940 | 7 | 0.0001 |
| Non-small cell lung cancer:05223 | 6 | 0.0003 |
| VEGF signaling pathway:04370 | 7 | 0.0003 |
| Metabolic pathways:01100 | 141 | 3.24e–17 |
| Olfactory transduction:04740 | 115 | 4.84e–12 |
| MAPK signaling pathway:04010 | 48 | 3.22e–12 |
| Pathways in cancer:05200 | 53 | 2.28e–11 |
| Ribosome:03010 | 23 | 6.46e–10 |
| FC epsilon RI signaling pathway:04664 | 21 | 2.54e–09 |
| Cell cycle:04110 | 27 | 3.83e–09 |
| Long term depression:04730 | 19 | 5.84e–09 |
| Gap junction:04540 | 21 | 1.65e–08 |
| Vascular smooth muscle contraction:04270 | 24 | 4.09e–08 |
| MAPK signaling pathway:04010 | 58 | 1.10e–21 |
| Metabolic pathways:01100 | 104 | 2.33e–09 |
| VEGF signaling pathway:04370 | 19 | 5.06e–09 |
| Neurotropin signaling pathway:04722 | 25 | 9.26e–09 |
| Pathways in cancer:05200 | 42 | 2.58e–08 |
| Chronic myeloid leukemia:05220 | 17 | 4.77e–07 |
| Toll-like receptor signaling pathway:04620 | 18 | 7.50e–07 |
| GnRH signaling pathway:04912 | 16 | 1.93e–05 |
| Leukocyte transendothelial migration:04670 | 18 | 2.29e–05 |
| FC epsilon RI signaling pathways:04664 | 14 | 2.75e–05 |
| MAPK signaling pathway:04010 | 56 | 9.54e–19 |
| Pathways in cancer:05200 | 53 | 8.51e–13 |
| Adipocytokine signaling pathway:04920 | 22 | 1.95e–12 |
| Metabolic pathways:01100 | 116 | 3.16e–11 |
| VEGF signaling pathway:04370 | 19 | 1.68e–08 |
| Neuroactive ligand receptor interaction:04080 | 36 | 1.80e–07 |
| Jak-STAT signaling pathway:04630 | 25 | 2.22e–07 |
| Leukocyte transendothelial migration:04670 | 22 | 3.05e–07 |
| Regulation of actin cytoskeleton:04810 | 31 | 4.89e–07 |
| Toll-like receptor signaling pathway:04620 | 19 | 4.78e–07 |
| MAPK signaling pathway:04010 | 63 | 2.05e–23 |
| Metabolic pathways:01100 | 125 | 9.13e–14 |
| Pathways in cancer:05200 | 50 | 5.84e–11 |
| Cytokine-cytokine receptor interaction:04060 | 35 | 5.59e–10 |
| Adipocytokine signaling pathway:04920 | 17 | 6.23e–08 |
| Focal adhesion:04510 | 31 | 8.65e–08 |
| P53 signaling pathway:04115 | 17 | 3.64e–07 |
| Neuroactive ligand receptor interaction:04080 | 35 | 7.63e–07 |
| Calcium signaling pathway:04020 | 28 | 1.25e–06 |
| Neutrotrophin signaling pathway:04722 | 22 | 3.15e–06 |
| Pathways in cancer:05200 | 74 | 3.25e–25 |
| MAPK signaling pathway:04010 | 62 | 3.30e–22 |
| Metabolic pathways:01100 | 127 | 8.15e–14 |
| Jak-STAT signaling pathway:04630 | 35 | 1.15e–13 |
| Neuroactive ligand receptor interaction:04080 | 44 | 4.00e–11 |
| Chronic myeloid leukemia:05220 | 23 | 6.70e–11 |
| Cytokine-cytokine receptor interaction:04060 | 37 | 6.25e–11 |
| Focal adhesion:04510 | 35 | 8.43e–10 |
| Prostate cancer:05215 | 23 | 1.01e–09 |
| Pancreatic cancer:05212 | 19 | 1.20e–08 |
| Cytokine-cytokine receptor interaction:04060 | 12 | 7.82e–05 |
| Pathways in cancer:05200 | 15 | 0.0003 |
| Chemokine signaling pathway:04062 | 9 | 0.0018 |
| MAPK signaling pathway:04010 | 11 | 0.0038 |
| Toll-like receptor signaling pathway:04620 | 6 | 0.0038 |
| Olfactory transduction:04740 | 28 | 0.0032 |
| Apoptosis:04210 | 6 | 0.0047 |
| Arachidonic acid metabolism:00590 | 5 | 0.0058 |
| Jak-STAT signaling pathway:04630 | 7 | 0.0086 |
| TGF beta signaling pathway:04350 | 5 | 0.0103 |
| Neuroactive ligand receptor interaction:04080 | 23 | 2.38e–07 |
| Prostate cancer:05215 | 13 | 6.23e–07 |
| Pathways in cancer:05200 | 24 | 4.38e–06 |
| Ribosome:03010 | 11 | 1.22e–05 |
| Focal adhesion:04510 | 16 | 4.16e–05 |
| Regulation of actin cytoskeleton:04810 | 17 | 3.59e–05 |
| Melanoma:05218 | 9 | 8.38e–05 |
| Olfactory transduction:04740 | 44 | 0.0004 |
| Cell adhesion molecule:04514 | 12 | 0.0006 |
| Wnt signaling pathway:04310 | 11 | 0.0011 |
Wiki functionally enriched pathway categories generated from genes significantly differentially expressed at .
| Cytoplasmic ribosomal proteins:WP30 | 17 | 3.08e–09 |
| MAPK signaling pathway:WP358 | 14 | 2.17e–05 |
| IL-5 signaling pathway:WP44 | 9 | 4.29e–05 |
| Insulin signaling:WP439 | 13 | 7.33e–05 |
| B cell receptor signaling pathway:WP285 | 13 | 0.0001 |
| Diurnally regulated genes with circadian orthologs:WP1306 | 6 | 0.0005 |
| TGF beta receptor signaling pathway:WP362 | 11 | 0.0005 |
| Adipogenesis:WP155 | 10 | 0.0008 |
| Fas pathway and stress induction of HSP regulation:WP89 | 6 | 0.0007 |
| IL-6 signaling pathway:WP135 | 9 | 0.0008 |
| Biosynthesis of aldosterone and cortisol:WP508 | 2 | 0.0038 |
| Diurnally regulated genes with circadian orthologs:WP1306 | 4 | 0.0037 |
| Steroid biosynthesis:WP66 | 2 | 0.0070 |
| TNF alpha NF-kB signaling pathway:WP457 | 6 | 0.0579 |
| GPCRs, class A rhodopsin-like:WP473 | 7 | 0.0485 |
| Kit receptor signaling pathway:WP147 | 4 | 0.0206 |
| Inflammatory response pathway:WP40 | 2 | 0.0666 |
| Cytokines and inflammatory response:WP271 | 2 | 0.0494 |
| Ovarian infertility genes:WP263 | 2 | 0.0535 |
| Metapathway biotransformation:WP1286 | 5 | 0.0379 |
| MAPK signaling pathway:WP358 | 29 | 2.69e–09 |
| EGFR1 signaling pathway:WP5 | 29 | 3.80e–08 |
| TNF alpha NF-KB signaling pathway:WP457 | 30 | 3.17e–08 |
| Insulin signaling:WP439 | 25 | 4.32e–07 |
| Renin-angiotensin system:WP376 | 13 | 3.97e–07 |
| Myometrial relaxation and contraction pathways:WP140 | 24 | 5.98e–07 |
| Regulation of actin cytoskeleton:WP351 | 24 | 6.89e–07 |
| G protein signaling pathways:WP73 | 18 | 1.14e–06 |
| IL-5 signaling pathway:WP44 | 15 | 3.31e–06 |
| B cell receptor signaling pathway:WP285 | 24 | 5.24e–06 |
| MAPK signaling pathway:WP358 | 36 | 2.63e–16 |
| Insulin signaling:WP439 | 31 | 1.25e–12 |
| TGF beta receptor signaling pathway:WP362 | 25 | 2.96e–09 |
| GPCRs, class A rhodopsin-like:WP473 | 32 | 4.84e–09 |
| Adipogenesis:WP155 | 23 | 6.55e–09 |
| EGFR1 signaling pathway:WP5 | 26 | 7.67e–08 |
| IL-6 signaling pathway:WP135 | 19 | 1.53e–07 |
| Toll-like receptor signaling pathway:WP1309 | 16 | 5.76e–07 |
| IL-3 signaling pathway:WP319 | 18 | 5.39e–07 |
| B cell receptor signaling pathway:WP285 | 23 | 1.21e–06 |
| MAPK signaling pathway:WP358 | 38 | 6.26e–17 |
| Adipogenesis:WP155 | 28 | 5.99e–12 |
| EGFR1 signaling pathway:WP5 | 33 | 1.42e–11 |
| B cell receptor signaling pathway:WP285 | 28 | 5.19e–09 |
| Insulin signaling:WP439 | 27 | 4.64e–09 |
| IL-3 signaling pathway:WP319 | 21 | 1.29e–08 |
| IL-6 signaling pathway:WP135 | 21 | 1.93e–08 |
| Toll-like receptor signaling pathway:WP1309 | 18 | 5.10e–08 |
| Delta notch signaling pathway:WP199 | 18 | 5.10e–08 |
| TNF alpha NF-KB signaling pathway:WP457 | 28 | 6.69e–08 |
| MAPK signaling pathway:WP358 | 33 | 8.27e–13 |
| Insulin signaling:WP439 | 31 | 1.27e–11 |
| Adipogenesis:WP155 | 27 | 5.08e–11 |
| EGFR1 signaling pathway:WP5 | 31 | 4.54e–10 |
| Apoptosis mechanisms:WP284 | 21 | 1.50e–09 |
| Apoptosis:WP1290 | 21 | 1.91e–09 |
| Diurnally regulated genes with circadian orthologs:WP1306 | 13 | 6.73e–09 |
| Cardiovascular signaling:WP590 | 14 | 3.15e–08 |
| Toll-like receptor signaling pathway:WP1309 | 24 | 7.80e–08 |
| T cell receptor signaling pathway:WP352 | 23 | 9.49e–08 |
| MAPK signaling pathway:WP358 | 40 | 4.75e–18 |
| Adipogenesis:WP155 | 33 | 1.25e–15 |
| EGFR1 signaling pathway:WP5 | 39 | 2.01e–15 |
| Insulin signaling:WP439 | 35 | 2.93e–14 |
| B cell receptor signaling pathway:WP285 | 33 | 5.96e–12 |
| IL-6 signaling pathway:WP135 | 26 | 5.32e–12 |
| Delta notch signaling pathway:WP199 | 21 | 3.62e–10 |
| TGF beta signaling pathways:WP505 | 17 | 6.00e–10 |
| GPCRs, class A rhodopsin-like:WP473 | 34 | 5.30e–09 |
| TGF beta receptor signaling pathway:WP362 | 26 | 6.09e–09 |
| Delta notch signaling pathway:WP199 | 8 | 2.30e–05 |
| Kit receptor signaling pathway:WP147 | 7 | 6.36e–05 |
| IL-5 signaling pathway:WP44 | 7 | 7.03e–05 |
| IL-3 signaling pathway:WP319 | 7 | 0.0007 |
| IL-6 signaling pathway:WP135 | 7 | 0.0007 |
| TGF beta signaling pathways:WP505 | 5 | 0.0011 |
| Toll-like receptor signaling pathway:WP1309 | 6 | 0.0012 |
| Notch signaling pathway:WP517 | 4 | 0.0017 |
| Endochondral ossification:WP1308 | 5 | 0.0017 |
| Hedgehog signaling pathway:WP574 | 3 | 0.0026 |
| Adipogenesis:WP155 | 11 | 0.0001 |
| GPCRs, class A rhodopsin-like:WP473 | 15 | 0.0002 |
| B cell receptor signaling pathway:WP285 | 12 | 0.0004 |
| Hypothetical network for drug addiction:WP1281 | 5 | 0.0007 |
| IL-6 signaling pathway:WP135 | 9 | 0.0006 |
| Regulation of actin cytoskeleton:WP351 | 11 | 0.0006 |
| Calcium regulation in the cardiac cell:WP326 | 10 | 0.0009 |
| Cytoplasmic ribosomal proteins:WP30 | 9 | 0.0017 |
| Androgen receptor signaling pathway:WP68 | 9 | 0.0019 |
| Myometrial relaxation and contraction pathways:WP140 | 10 | 0.0019 |
Effect of exercise on stress-induced alterations in the expression of select genes in the DRN.
Figure 4Effect of exercise on stress-induced alterations in the expression of select genes in the DRN, organized by Wiki functional category.
Figure 5Effect of exercise and/or stress on modules of coexpressed genes in the DRN.
KEGG functionally enriched pathway categories generated from modules of genes correlated to exercise and/or stress.
| Focal adhesion:04510 | 3 | 0.0014 |
| Type II diabetes mellitus:04930 | 2 | 0.0015 |
| Pancreatic cancer:05212 | 2 | 0.0031 |
| Colorectal cancer:05210 | 2 | 0.0047 |
| Pathways in cancer:05200 | 3 | 0.0061 |
| Neurotropin signaling pathway:04722 | 2 | 0.0099 |
| Insulin signaling pathway:04910 | 2 | 0.0099 |
| Ubiquitin mediated proteolysis:04120 | 2 | 0.0091 |
| Metabolic Pathways:01100 | 2 | 0.3704 |
| Metabolic Pathways:01100 | 231 | 3.92e–38 |
| Ribosome:03010 | 43 | 7.08e–24 |
| Ubiquitin mediated proteolysis:04120 | 45 | 9.21e–18 |
| Axon guidance:04360 | 42 | 6.30e–15 |
| Huntington's disease:05016 | 56 | 2.63e–13 |
| Alzheimer's disease:05010 | 57 | 7.96e–13 |
| Oxidative phosphorylation:00190 | 43 | 3.01e–12 |
| Regulation of actin cytoskeleton:04810 | 51 | 3.72e–12 |
| Spliceosome:03040 | 37 | 3.89e–12 |
| Cell cycle:04110 | 37 | 5.05e–12 |
| Cytokine-cytokine receptor interaction:04060 | 4 | 0.0005 |
| Prion Diseases:05020 | 2 | 0.0020 |
| Wnt signaling pathway:04310 | 3 | 0.0023 |
| MAPK signaling pathway:04010 | 4 | 0.0014 |
| Chemokine signaling pathway:04062 | 3 | 0.0039 |
| Toll-like receptor signaling pathway:04620 | 2 | 0.0127 |
| VEGF signaling pathway:04370 | 2 | 0.0087 |
| GnRH signaling pathway:04912 | 2 | 0.0132 |
| Apoptosis:04210 | 2 | 0.0137 |
| Small cell lung cancer:05222 | 2 | 0.0127 |
| MAPK signaling pathway:04010 | 23 | 3.94e–15 |
| Cytokine-cytokine receptor interaction:04060 | 13 | 9.53e–08 |
| Jak-Stat signaling pathway:04630 | 10 | 2.02e–06 |
| Adipocytokine signaling pathway:04920 | 7 | 4.19e–06 |
| Pathways in cancer:05200 | 14 | 6.26e–06 |
| Hematopoietic cell lineage:04640 | 7 | 1.07e–05 |
| P53 signaling pathway:04115 | 6 | 9.48e–05 |
| Focal adhesion:04510 | 9 | 0.0002 |
| Chronic myeloid leukemia:05220 | 6 | 0.0002 |
| ErbB signaling pathway:04012 | 6 | 0.0002 |
Wiki functionally enriched pathway categories generated from modules of genes correlated to exercise and/or stress.
| Insulin signaling:WP439 | 3 | 0.0005 |
| Apoptosis:WP1290 | 2 | 0.0039 |
| IL-3 signaling pathway:WP319 | 2 | 0.0048 |
| Apoptosis mechanisms:WP284 | 2 | 0.0038 |
| mRNA processing:WP529 | 41 | 2.45e–17 |
| Electron transport chain:WP59 | 35 | 6.06e–17 |
| TNF alpha NF-KB signaling pathway:WP457 | 47 | 2.77e–14 |
| EGFR1 signaling pathway:WP5 | 42 | 6.39e–12 |
| Regulation of actin cytoskeleton:WP351 | 37 | 2.25e–11 |
| TGF beta receptor signaling pathway:WP362 | 35 | 1.04e–10 |
| B cell receptor signaling pathway:WP285 | 38 | 1.96e–10 |
| G protein signaling pathway:WP73 | 27 | 2.60e–10 |
| Oxidative phosphorylation:WP1283 | 19 | 3.28e–09 |
| Proteasome degradation:WP302 | 19 | 1.51e–08 |
| Hypertrophy Model:WP442 | 3 | 4.38e–06 |
| Insulin signaling:WP429 | 4 | 0.0001 |
| GPCRs, class A rhodopsin-like:WP473 | 4 | 0.0005 |
| Small ligand GPCRs:WP161 | 2 | 0.0004 |
| Prostaglandin synthesis and regulation:WP303 | 2 | 0.0012 |
| Myometrial relaxation and contraction pathways:WP140 | 3 | 0.0018 |
| MAPK signaling pathway:WP358 | 3 | 0.0022 |
| TGF beta receptor signaling pathway:WP362 | 3 | 0.0016 |
| Diurnally regulated genes with circadian orthologs:WP1306 | 2 | 0.0022 |
| Peptide GPCRs:WP131 | 2 | 0.0043 |
| MAPK signaling pathway:WP358 | 15 | 1.29e–11 |
| Adipogenesis:WP155 | 12 | 1.41e–09 |
| Insulin signaling:WP429 | 9 | 1.04e–05 |
| TGF beta receptor signaling pathway:WP362 | 8 | 3.95e–05 |
| IL-6 signaling pathway:WP135 | 7 | 4.22e–05 |
| Triacylglyercide synthesis:WP356 | 4 | 4.69e–05 |
| ErbB signaling pathway:WP1299 | 5 | 7.64e–05 |
| P38 MAPK signaling pathway:WP294 | 4 | 0.0002 |
| GPCRs, class A rhodopsin-like:WP473 | 9 | 0.0002 |
| Wnt signaling pathway and pluripotency:WP1288 | 6 | 0.0002 |
| TNF alpha NF-KB signaling pathway:WP457 | 5 | 7.31e–05 |
| Electron transport chain:WP59 | 3 | 0.0013 |
| Androgen receptor signaling pathway:WP68 | 3 | 0.0029 |
| Cytoplasmic ribosomal proteins:WP30 | 3 | 0.0028 |
| Oxidative phosphorylation:WP1283 | 2 | 0.0070 |
| Proteasome degradation:WP302 | 2 | 0.0081 |
| G1 to S cell cycle control:WP348 | 2 | 0.0110 |
| Wnt signaling pathway:WP375 | 2 | 0.0227 |
Functional role of proteins encoded by genes of interest.
| Transcription factor: can inhibit or activate transcription | |
| Enzyme: participates in variety of cellular processes by reversible protein phosphorylation | |
| Not clear: potential oncogene and regulator of latent HIV | |
| Enzyme: catalyzes the synthesis of retinoic acid from retinaldehyde | |
| Enzyme: catalyzes 1st and rate-limiting step in a major pathway of tryptophan metabolism, L-tryptophan > n-formyl kynurenine | |
| Substrate: role in antigen receptor signaling, potential role in regulation of gene expression | |
| Enzyme: catalyze hydrolysis of phospholipids | |
| Ligase: negatively regulates T-cell and B-cell receptors | |
| Enzyme: may help couple Fc receptor to activation of respiratory burst, potential role in neutrophil migration and degranulation of neutrophils | |
| Cytokine: forms a gene cluster w/ IL-3, IL-5, IL-13 on chromosome 5q, costimulator of DNA synthesis, induces expression of MHC II on B-cells | |
| Cytokine: controls proliferation, differentiation, regulation of other growth factors | |
| Receptor: related to type 1 receptors of TGF-β family | |
Figure 6mRNA expression of 5-HT1A in the DRN.